What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering.
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end.
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price objective, citing the potential of its lead drug candidate to reshape first-line treatment for a form of head and neck cancer, according to a research note published Tuesday. The analysts pointed to the company's lead asset ficerafusp alfa (ficera) as the central driver of their outlook.
Bicara Therapeutics Inc. (BCAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Bicara Therapeutics Inc. (BCAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout
Bicara Therapeutics (BCAX) is initiated with a Buy rating, driven by promising data for its HNSCC candidate, Ficera. Ficera's Phase 1b results in HPV-negative HNSCC show strong efficacy, outperforming current standards, albeit rival Merus' petosemtamab data is arguably stronger. BCAX benefits from FDA Breakthrough Therapy Designation, robust cash reserves, and potential for blockbuster revenues if successful.
